Selecta Biosciences (SELB) is trading 31% higher at $2.16 today.
- Revenue grew +99.73% Y/Y to $39.27M
- GAAP EPS of $0.06 (beats by $0.14)
- End of Q2 Cash, cash equivalents, and short term investments were at $143.4M
Selecta Biosciences has been trading between a 52-week high of $4.7 and a 52-week low of $0.6469. The stock has a market cap of $328 Million.
Selecta Biosciences Inc. is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body's natural self-tolerance in autoimmune diseases.
Selecta stock rises 13% on Q2 beat while revenue doublesSeeking Alpha
Selecta Biosciences GAAP EPS of $0.06 beats by $0.14, revenue of $39.3M beats by $25.52MSeeking Alpha
Hypnotizing stocks: Selecta Biosciences, Inc. (NASDAQ:SELB -2.37%), Regulus Therapeutics Inc. (NASDAQ:RGLS -8.90%)Stock Equity
Thinking about buying stock in Applied UV, Nio, Wejo Group, Helius Medical Technologies, or Selecta Biosciences?Benzinga
Selecta Biosciences Inc. (NASDAQ: SELB) Stock: Can Value Hunters Buy It?Stocks Register